Acadia Healthcare's Stock Upgrade and Strategic Review

Font: Financial Modeling Prep  • Oct 03, 2025

• Raymond James upgraded Acadia Healthcare (NASDAQ:ACHC) to "Outperform" with a new price target of $30.
• Khrom Capital Management calls for a strategic review of Acadia Healthcare, including a potential sale.
• ACHC's stock price has increased by 8.43%, reflecting growing investor interest despite challenges.

Acadia Healthcare (NASDAQ:ACHC) is a leading provider of behavioral healthcare services. The company operates a network of facilities offering a range of services, including psychiatric and addiction treatment. Acadia competes with other healthcare providers in the behavioral health sector, striving to deliver quality care and expand its market presence.

On October 3, 2025, Raymond James upgraded its rating for ACHC to "Outperform," signaling confidence in the stock's potential. At the time, ACHC was priced at $26.62. Raymond James also increased the price target from $26 to $30, suggesting an optimistic outlook for the company's future performance.

Khrom Capital Management, a major shareholder, has called for a strategic review, including a potential sale, due to perceived governance failures and poor performance. This highlights ongoing challenges within Acadia Healthcare, despite the recent positive stock movement.

ACHC's stock price has seen an 8.43% increase, or $2.07, reflecting investor interest. The stock fluctuated between $24.57 and $26.72 during the day. Over the past year, ACHC has experienced significant volatility, with a high of $60.52 and a low of $17.13.

Acadia Healthcare's market capitalization stands at approximately $2.46 billion, indicating its size in the market. The trading volume for ACHC today is 3,511,931 shares on the NASDAQ exchange, showing active investor engagement.